Combined therapeutic approach: Inflammatory bowel diseases and peripheral or axial arthritis

World Journal of Gastroenterology

Volumn 15, Issue 20, 2009, Pages 2469-2471

  Atzeni, Fabiola ^a   Ardizzone, Sandro ^a   Bertani, Luca ^a   Antivalle, Marco ^a   Batticciotto, Alberto ^a   Sarzi Puttini, Piercarlo ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Anti tumor necrosis factor antagonists; Arthropathies; Inflammatory bowel disease; Treatment

Indexed keywords

ADALIMUMAB; ANALGESIC AGENT; ETANERCEPT; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; ONERCEPT; SALAZOSULFAPYRIDINE; STEROID; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; IMMUNOSUPPRESSIVE AGENT; TUMOR NECROSIS FACTOR ALPHA;

ARTHRITIS; ARTICLE; AXIAL ARTHRITIS; CROHN DISEASE; ENTERITIS; HUMAN; JOINT RADIOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PERIPHERAL ARTHRITIS; PHYSIOTHERAPY; ULCERATIVE COLITIS; DRUG ANTAGONISM; IMMUNOLOGY; PATHOLOGY;

ARTHRITIS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 67650133676     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.15.2469     Document Type: Article

References (26)

1. Ardizzone S, Puttini PS, Cassinotti A, Porro GB. Extraintestinal manifestations of inflammatory bowel disease. Dig Liver Dis 2008; 40 Suppl 2: S253-S259
2. Su CG, Judge TA, Lichtenstein GR. Extraintestinal manifestations of inflammatory bowel disease. Gastroenterol Clin North Am 2002; 31: 307-327
3. Urlep D, Mamula P, Baldassano R. Extraintestinal manifestations of inflammatory bowel disease. Minerva Gastroenterol Dietol 2005; 51: 147-163
4. Orchard TR, Wordsworth BP, Jewell DP. Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history. Gut 1998; 42: 387-391
5. Fornaciari G, Salvarani C, Beltrami M, Macchioni P, Stockbrügger RW, Russel MG. Muscoloskeletal manifestations in inflammatory bowel disease. Can J Gastroenterol 2001; 15: 399-403
6. Bjarnason I, Helgason KO, Geirsson AJ, Sigthorsson G, Reynisdottir I, Gudbjartsson D, Einarsdottir AS, Sherwood R, Kristjansson K, Kjartansson O, Thjodleifsson B. Subclinical intestinal inflammation and sacroiliac changes in relatives of patients with ankylosing spondylitis. Gastroenterology 2003; 125: 1598-1605
7. Heuft-Dorenbosch L, Landewé R, Weijers R, Wanders A, Houben H, van der Linden S, van der Heijde D. Combining information obtained from magnetic resonance imaging and conventional radiographs to detect sacroiliitis in patients with recent onset inflammatory back pain. Ann Rheum Dis 2006; 65: 804-808
8. Zochling J, Baraliakos X, Hermann KG, Braun J. Magnetic resonance imaging in ankylosing spondylitis. Curr Opin Rheumatol 2007; 19: 346-352
9. Steer S, Jones H, Hibbert J, Kondeatis E, Vaughan R, Sanderson J, Gibson T. Low back pain, sacroiliitis, and the relationship with HLA-B27 in Crohn's disease. J Rheumatol 2003; 30: 518-522
10. Dale J, Alcorn N, Capell H, Madhok R. Combination therapy for rheumatoid arthritis: methotrexate and sulfasalazine together or with other DMARDs. Nat Clin Pract Rheumatol 2007; 3: 450-458; quiz, following 478
11. Akkoc N, van der Linden S, Khan MA. Ankylosing spondylitis and symptom-modifying vs disease-modifying therapy. Best Pract Res Clin Rheumatol 2006; 20: 539-557
12. Caporali R, Pallavicini FB, Filippini M, Gorla R, Marchesoni A, Favalli EG, Sarzi-Puttini P, Atzeni F, Montecucco C. Treatment of rheumatoid arthritis with anti-TNF-alpha agents: a reappraisal. Autoimmun Rev 2009; 8: 274-280
13. Chen J, Liu C. Sulfasalazine for ankylosing spondylitis. Cochrane Database Syst Rev 2005: CD004800
14. Takeuchi K, Smale S, Premchand P, Maiden L, Sherwood R, Thjodleifsson B, Bjornsson E, Bjarnason I. Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2006; 4: 196-202
15. Sandborn WJ, Stenson WF, Brynskov J, Lorenz RG, Steidle GM, Robbiris JL, Kent JD, Bloom BJ. Safety of celecoxib in patients with ulcerative colitis in remission: a randomized, placebo-controlled, pilot study. Clin Gastroenterol Hepatol 2006; 4: 203-211
16. Zochling J, van der Heijde D, Burgos-Vargas R, Collantes E, Davis JC Jr, Dijkmans B, Dougados M, Géher P, Inman RD, Khan MA, Kvien TK, Leirisalo-Repo M, Olivieri I, Pavelka K, Sieper J, Stucki G, Sturrock RD, van der Linden S, Wendling D, Böhm H, van Royen BJ, Braun J. ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2006; 65: 442-452
17. Barrie A, Regueiro M. Biologic therapy in the management of extraintestinal manifestations of inflammatory bowel disease, lnflamm Bowel Dis 2007; 13: 1424-1429
18. Ellman MH, Hanauer S, Sitrin M, Cohen R. Crohn's disease arthritis treated with infliximab: an open trial in four patients. J Clin Rheumatol 2001; 7: 67-71
19. Herfarth H, Obermeier F, Andus T, Rogler G, Nikolaus S, Kuehbacher T, Schreiber S. Improvement of arthritis and arthralgia after treatment with infliximab (Remicade) in a German prospective, open-label, multicenter trial in refractory Crohn's disease. Am J Gastroenterol 2002; 97: 2688-2690
20. Kaufman I, Caspi D, Yeshurun D, Dotan I, Yaron M, Elkayam O. The effect of infliximab on extraintestinal manifestations of Crohn's disease. Rheumatol Int 2005; 25: 406-410
21. Devlin SM, Panaccione R. Adalimumab for the treatment of Crohn's disease. Expert Opin Biol Ther 2008; 8: 1011-1019
22. Generini S, Giacomelli R, Fedi R, Fulminis A, Pignone A, Frieri G, Del Rosso A, Viscido A, Galletti B, Fazzi M, Tonelli F, Matucci-Cerinic M. Infliximab in spondyloarthropathy associated with Crohn's disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations. Ann Rheum Dis 2004; 63: 1664-1669
23. Maksymowych WP. Update on the treatment of ankylosing spondylitis. Ther Clin Risk Manag 2007; 3: 1125-1133
24. Braun J, Baraliakos X, Listing J, Davis J, van der Heijde D, Haibel H, Rudwaleit M, Sieper J. Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents. Arthritis Rheum 2007; 57: 639-647
25. van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BA, Braun J, Dougados M, Reveille JD, Wong RL, Kupper H, Davis JC Jr. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006; 54: 2136-2146
26. Antivalle M, Bertani L, Atzeni F, Battellino M, Batticciotto A, Montalbano F, Mutti A, Sarzi-Puttini P. Disease activity and quality of life in Crohn's-associated spondyloarthropathy after switching from infliximab to adalimumab. Clin Exp Rheum 2008; 26: 746